Comparative Pharmacology
Head-to-head clinical analysis: DECLOMYCIN versus TETRACYCLINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECLOMYCIN versus TETRACYCLINE HYDROCHLORIDE.
DECLOMYCIN vs TETRACYCLINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting aminoacyl-tRNA binding to the mRNA-ribosome complex, thereby blocking protein synthesis.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
150 mg orally every 6 hours or 300 mg orally every 12 hours.
250-500 mg orally every 6 hours; or 500 mg to 1 g intravenously every 12 hours. Maximum oral dose: 4 g/day.
None Documented
None Documented
Terminal elimination half-life 10-17 hours; prolonged to 18-48 hours in renal impairment
6-11 hours (prolonged to 57-120 hours in severe renal impairment; reduced in hepatic dysfunction; clinically relevant for dosing interval adjustments).
Renal: ~50% unchanged; biliary/fecal: ~40% as inactive metabolites; enterohepatic recycling occurs
Renal (60% unchanged via glomerular filtration), biliary (40% as active drug and metabolites, with enterohepatic recirculation; fecal elimination of unabsorbed drug).
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic